
Bifidobacterium breve is a well-known probiotic bacterium from the infant gut, studied mainly in infants and in small trials on reducing body fat in adults.
What is the bacterium
Bifidobacterium breve is a "friendly" bacterium of the genus Bifidobacterium, one of the most common groups in probiotic supplements. It is the dominant bifidobacterium in the gut of breastfed newborns, was first isolated from infant stool, and is also found in breast milk. It has enzymes that allow it to break down complex sugars, including the unique sugars in breast milk.
Good to know: the effect depends on the strain
The effects of probiotics depend on the specific strain (for example M-16V or B-3), and a benefit found for one strain does not guarantee a similar benefit for another. It is therefore important to read research findings in the context of the strain that was tested.
What the research says
- Premature infants: small studies have linked B. breve strains to faster colonization by beneficial bacteria and fewer intestinal complications. However, a 2019 systematic review found no significant benefit in the controlled trials, and the quality of the evidence was rated as very low.
- Allergy and eczema in children: some studies have shown a reduction in symptoms, usually in combination with other strains.
- Body fat in adults: in two double-blind trials from Japan, the B-3 strain given for 12 weeks to overweight adults led to a moderate reduction in fat mass and waist circumference compared with placebo. These were small trials, partly funded by the manufacturer, and have not been independently replicated.
Overall, there are promising findings but partial evidence, mostly based on specific strains and limited populations.
Safety
B. breve is included in the "qualified presumption of safety" (QPS) list of the European Food Safety Authority, and according to reviews it does not carry transferable antibiotic resistance genes. No serious side effects were reported in the trials. According to NCCIH, people with serious illness or a weakened immune system, as well as premature infants, are at higher risk of infections from probiotics, so consult a doctor before use.
In summary: B. breve is a natural bacterium of the infant gut, with a good safety profile, and has been studied in various areas. Most of the positive findings relate to specific strains and small studies, so it is too early to draw broad conclusions from them.